Cyramza (ramucirumab)

News alerts, weekly reports and conference planners

Company:

Eli Lilly, Innovent Biologics

Drug class:

VEGFR-2 inhibitor

Related drugs:

No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1
AFP elevation	Hepatocellular Cancer	AFP elevation	Hepatocellular Cancer	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	erlotinib + ramucirumab Sensitive: A1 - Approval erlotinib + ramucirumab Sensitive : A1	erlotinib + ramucirumab Sensitive: A1 - Approval erlotinib + ramucirumab Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	erlotinib + ramucirumab Sensitive: A1 - Approval erlotinib + ramucirumab Sensitive : A1	erlotinib + ramucirumab Sensitive: A1 - Approval erlotinib + ramucirumab Sensitive : A1
No biomarker	Esophageal Adenocarcinoma	No biomarker	Esophageal Adenocarcinoma	ramucirumab Sensitive: A2 - Guideline ramucirumab Sensitive : A2	ramucirumab Sensitive: A2 - Guideline ramucirumab Sensitive : A2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	erlotinib + ramucirumab Sensitive: A2 - Guideline erlotinib + ramucirumab Sensitive : A2	erlotinib + ramucirumab Sensitive: A2 - Guideline erlotinib + ramucirumab Sensitive : A2
EGFR expression	Non Small Cell Lung Cancer	EGFR expression	Non Small Cell Lung Cancer	erlotinib + ramucirumab Sensitive: A2 - Guideline erlotinib + ramucirumab Sensitive : A2	erlotinib + ramucirumab Sensitive: A2 - Guideline erlotinib + ramucirumab Sensitive : A2
No biomarker	Lung Non-Small Cell Squamous Cancer	No biomarker	Lung Non-Small Cell Squamous Cancer	ramucirumab Sensitive: A2 - Guideline ramucirumab Sensitive : A2	ramucirumab Sensitive: A2 - Guideline ramucirumab Sensitive : A2
No biomarker	Rectal Cancer	No biomarker	Rectal Cancer	ramucirumab Sensitive: A2 - Guideline ramucirumab Sensitive : A2	ramucirumab Sensitive: A2 - Guideline ramucirumab Sensitive : A2
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	ramucirumab Sensitive: A2 - Guideline ramucirumab Sensitive : A2	ramucirumab Sensitive: A2 - Guideline ramucirumab Sensitive : A2
No biomarker	Colon Cancer	No biomarker	Colon Cancer	ramucirumab Sensitive: A2 - Guideline ramucirumab Sensitive : A2	ramucirumab Sensitive: A2 - Guideline ramucirumab Sensitive : A2
BRAF mutation	Colorectal Cancer	BRAF mutation	Colorectal Cancer	ramucirumab Sensitive: B - Late Trials ramucirumab Sensitive : B	ramucirumab Sensitive: B - Late Trials ramucirumab Sensitive : B
HER-2 negative	Gastroesophageal Junction Adenocarcinoma	HER-2 negative	Gastroesophageal Junction Adenocarcinoma	ramucirumab Sensitive: B - Late Trials ramucirumab Sensitive : B	ramucirumab Sensitive: B - Late Trials ramucirumab Sensitive : B
HER-2 negative	Gastric Cancer	HER-2 negative	Gastric Cancer	ramucirumab Sensitive: B - Late Trials ramucirumab Sensitive : B	ramucirumab Sensitive: B - Late Trials ramucirumab Sensitive : B
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	erlotinib + ramucirumab Sensitive: B - Late Trials erlotinib + ramucirumab Sensitive : B	erlotinib + ramucirumab Sensitive: B - Late Trials erlotinib + ramucirumab Sensitive : B
EGFR exon 19 mutation	Non Small Cell Lung Cancer	EGFR exon 19 mutation	Non Small Cell Lung Cancer	erlotinib + ramucirumab Sensitive: B - Late Trials erlotinib + ramucirumab Sensitive : B	erlotinib + ramucirumab Sensitive: B - Late Trials erlotinib + ramucirumab Sensitive : B
EGFR exon 21 mutation	Non Small Cell Lung Cancer	EGFR exon 21 mutation	Non Small Cell Lung Cancer	erlotinib + ramucirumab Sensitive: B - Late Trials erlotinib + ramucirumab Sensitive : B	erlotinib + ramucirumab Sensitive: B - Late Trials erlotinib + ramucirumab Sensitive : B
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	gefitinib + ramucirumab Sensitive: B - Late Trials gefitinib + ramucirumab Sensitive : B	gefitinib + ramucirumab Sensitive: B - Late Trials gefitinib + ramucirumab Sensitive : B
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	gefitinib + ramucirumab Sensitive: B - Late Trials gefitinib + ramucirumab Sensitive : B	gefitinib + ramucirumab Sensitive: B - Late Trials gefitinib + ramucirumab Sensitive : B
VEGFD elevation	Colorectal Cancer	VEGFD elevation	Colorectal Cancer	ramucirumab Sensitive: B - Late Trials ramucirumab Sensitive : B	ramucirumab Sensitive: B - Late Trials ramucirumab Sensitive : B
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	ramucirumab Sensitive: B - Late Trials ramucirumab Sensitive : B	ramucirumab Sensitive: B - Late Trials ramucirumab Sensitive : B
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	ramucirumab Sensitive: B - Late Trials ramucirumab Sensitive : B	ramucirumab Sensitive: B - Late Trials ramucirumab Sensitive : B
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	osimertinib + ramucirumab Sensitive: C2 – Inclusion Criteria osimertinib + ramucirumab Sensitive : C2	osimertinib + ramucirumab Sensitive: C2 – Inclusion Criteria osimertinib + ramucirumab Sensitive : C2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	ramucirumab Sensitive: C2 – Inclusion Criteria ramucirumab Sensitive : C2	ramucirumab Sensitive: C2 – Inclusion Criteria ramucirumab Sensitive : C2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	osimertinib + ramucirumab Sensitive: C2 – Inclusion Criteria osimertinib + ramucirumab Sensitive : C2	osimertinib + ramucirumab Sensitive: C2 – Inclusion Criteria osimertinib + ramucirumab Sensitive : C2
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	trastuzumab + ramucirumab Sensitive: C2 – Inclusion Criteria trastuzumab + ramucirumab Sensitive : C2	trastuzumab + ramucirumab Sensitive: C2 – Inclusion Criteria trastuzumab + ramucirumab Sensitive : C2
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	ramucirumab Sensitive: C2 – Inclusion Criteria ramucirumab Sensitive : C2	ramucirumab Sensitive: C2 – Inclusion Criteria ramucirumab Sensitive : C2
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	pembrolizumab + ramucirumab Sensitive: C2 – Inclusion Criteria pembrolizumab + ramucirumab Sensitive : C2	pembrolizumab + ramucirumab Sensitive: C2 – Inclusion Criteria pembrolizumab + ramucirumab Sensitive : C2
CXCL8 elevation	Gastric Cancer	CXCL8 elevation	Gastric Cancer	nivolumab + ramucirumab Sensitive: C3 – Early Trials nivolumab + ramucirumab Sensitive : C3	nivolumab + ramucirumab Sensitive: C3 – Early Trials nivolumab + ramucirumab Sensitive : C3

Cyramza (ramucirumab)

Associations
(59)

Associations
(59)

Cyramza (ramucirumab)

Associations(59)

Associations(59)

Associations
(59)

Associations
(59)